MAVERIX PROVIDES ANALYTIC SUPPORT TO RARE GENOMICS INSTITUTE COMPETITION TO ACCELERATE PERSONALIZED DISEASE RESEARCH

SAN MATEO, CA - Mar 3, 2015 - Maverix Biomics, Inc., a leading genomic analysis software company, today announced that it will provide $50,000 in analytic support to the Rare Genomics Institute (RGI) competition, BeHEARD (Helping Empower and Accelerate Research Discoveries), an annual rare disease science challenge. Bioinformatics support for the contest will be conducted on the Maverix Analytic Platform, a cloud-based solution that leverages proven open-source algorithms and applications developed at leading academic and research centers.

The RGI-hosted contest is aimed at accelerating personalized rare disease research and offering new options for patients suffering from hard-to-diagnose and treat ailments. The competition is open globally to researchers, foundations, or anyone whose idea is constrained due to limited resources. Research proposals will be evaluated by an expert panel of scientists, and prizes for the challenge include access to sponsored cutting-edge technology and services. Interested researchers can apply here: http://beheard2015.raregenomics.org/home

Maverix is pleased to be integrally involved in a program where our genomic analysis technology will further accelerate the understanding of a specific rare disease, said Dave Mandelkern, Maverix CEO. Bioinformatics is the key to advancing scientific discovery in rare disease research.

One or more winning research proposals in the BeHEARD challenge will have the opportunity to choose between two of Maverixs most popular analysis kits, the DNA-seq Exome variant analysis kit, or the mRNA-seq expression analysis kit. In addition to providing up to 100 analysis kits on the Maverix Analytic Platform, three months of free data storage will also be included.

About the Maverix Analytic Platform

The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analyses with reliable, scientifically vetted configurations, as cited in peer-reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including a private, secure version of the UCSC Genome Browser, the worlds most widely used genome browser.

About Maverix Biomics

Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. For more information, visit www.maverixbio.com.

About the Rare Genomics Institute

RGI is a non-profit that makes cutting edge research technologies and experts accessible to rare disease patients. Partnering with top medical institutions, such as Harvard, Yale, Johns Hopkins, and Stanford, RGI helps custom-design personalized research projects for diseases so rare that no organization exists to help. By providing an expert network and an online crowdfunding mechanism, RGI helps families source, design, and fund personalized research projects in diseases not otherwise studied. Ultimately, RGI aims to expand on its current genome sequencing-focused approach to enable community funding to support any type of research that leads to rare disease therapeutics. For more information about Rare Genomics Institute, visit http://www.raregenomics.org

###